IBL-302

Modify Date: 2024-01-16 18:08:09

IBL-302 structure	Common Name	IBL-302
	CAS Number	1414455-21-2	Molecular Weight	567.63
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₅H₁₈FN₅O₄S₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of IBL-302

IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab (HY-P9907) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629)[1][2][3].

Name	IBL-302

Description	IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab (HY-P9907) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629)[1][2][3].
Related Catalog	Signaling Pathways >> PI3K/Akt/mTOR >> mTOR Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> Pim Signaling Pathways >> PI3K/Akt/mTOR >> PI3K Signaling Pathways >> PI3K/Akt/mTOR >> Akt
References	[1]. Kennedy SP et al. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene. 2020 Apr;39(14):3028-3040. [2]. Kennedy S P, et al. Evaluation of dual-acting PIM/PI3K inhibitor IBL-302 in preclinical breast cancer models[J]. Cancer Research, 2018, 78(13_Supplement): 2932-2932. [3]. Martínez-González S, et al. Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors. ACS Med Chem Lett. 2021 Nov 2;12(11):1794-1801.

Description

Related Catalog

Signaling Pathways >> PI3K/Akt/mTOR >> mTOR

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> Pim

Signaling Pathways >> PI3K/Akt/mTOR >> PI3K

Signaling Pathways >> PI3K/Akt/mTOR >> Akt

References

[1]. Kennedy SP et al. Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene. 2020 Apr;39(14):3028-3040.

[2]. Kennedy S P, et al. Evaluation of dual-acting PIM/PI3K inhibitor IBL-302 in preclinical breast cancer models[J]. Cancer Research, 2018, 78(13_Supplement): 2932-2932.

[3]. Martínez-González S, et al. Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors. ACS Med Chem Lett. 2021 Nov 2;12(11):1794-1801.

Molecular Formula	C₂₅H₁₈FN₅O₄S₃
Molecular Weight	567.63

Dichloromethane
CAS#:75-09-2

Polyacrylic acid
CAS#:9003-01-4

sodium carbonate
CAS#:497-19-8

Silicon dioxide
CAS#:7631-86-9

Triethanolamine
CAS#:102-71-6

Demeton
CAS#:126-75-0

Water
CAS#:7732-18-5

4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9

Diclofenac sodium
CAS#:15307-79-6

Budesonide
CAS#:51372-29-3

IBL-302

Use of IBL-302

Names

IBL-302 Biological Activity

Chemical & Physical Properties